{"filing":{"accession_number":"0001193125-26-295622","cik":"0001595097","ticker":"CRBP","company_name":"Corbus Pharmaceuticals Holdings, Inc.","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"crbp-20260702.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526295622/crbp-20260702.htm"},"events":[{"id":16132,"run_id":14395,"accession_number":"0001193125-26-295622","anchor_item_number":"1.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Corbus Pharmaceuticals appointed Leonardo Viana Nicacio, M.D. as Chief Medical Officer, effective August 3, 2026, under a two-year employment agreement. Dr. Nicacio brings 20+ years of pharmaceutical development experience, including pivotal work on TIVDAK®, and expertise in ADCs and HPV-driven oncology directly aligned with the company's strategic priorities as it approaches initiation of the TEMPO-1 registrational study. The appointment includes material inducement equity awards of $2.1 million.","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":14130,"accession_number":"0001193125-26-295622","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the appointment of Leonardo Viana Nicacio, M.D. as Chief Medical Officer effective August 3, 2026, with a two-year employment agreement. While the Item 1.01 caption references a \"Material Definitive Agreement,\" the substantive disclosure centers on the executive appointment and the material inducement equity awards ($2.1M) granted to secure his employment. The press release (EX-99.1) explicitly announces his appointment as CMO, emphasizing his relevant oncology background as material to the Company's near-term clinical milestones. This is an exec_appointment rather than exec_compensation because the principal action is Dr. Nicacio taking a role, even though compensation details are disclosed.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-06T12:16:48.909721+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14131,"accession_number":"0001193125-26-295622","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Leonardo Viana Nicacio as Chief Medical Officer of Corbus Pharmaceuticals, effective July 6, 2026. The press release emphasizes his extensive 20+ year background in pharmaceutical development, his pivotal role advancing TIVDAK® to market, and his relevant expertise in ADCs and HPV-driven oncology—directly aligned with the company's strategic priorities as it approaches initiation of the TEMPO-1 registrational study. This is a material executive appointment to a named officer position at a clinical-stage company with near-term clinical milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-06T12:16:48.909721+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14130,"accession_number":"0001193125-26-295622","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the appointment of Leonardo Viana Nicacio, M.D. as Chief Medical Officer effective August 3, 2026, with a two-year employment agreement. While the Item 1.01 caption references a \"Material Definitive Agreement,\" the substantive disclosure centers on the executive appointment and the material inducement equity awards ($2.1M) granted to secure his employment. The press release (EX-99.1) explicitly announces his appointment as CMO, emphasizing his relevant oncology background as material to the Company's near-term clinical milestones. This is an exec_appointment rather than exec_compensation because the principal action is Dr. Nicacio taking a role, even though compensation details are disclosed.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-06T12:16:48.909721+00:00","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-07-06"},{"id":14131,"accession_number":"0001193125-26-295622","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Leonardo Viana Nicacio as Chief Medical Officer of Corbus Pharmaceuticals, effective July 6, 2026. The press release emphasizes his extensive 20+ year background in pharmaceutical development, his pivotal role advancing TIVDAK® to market, and his relevant expertise in ADCs and HPV-driven oncology—directly aligned with the company's strategic priorities as it approaches initiation of the TEMPO-1 registrational study. This is a material executive appointment to a named officer position at a clinical-stage company with near-term clinical milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-06T12:16:48.909721+00:00","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-07-06"}]}